Table 2.

Seroprevalence of Antibodies to Poliovirus Types 1, 2, and 3, by Age, Among Infants 6–12 Months of Age, Moradabad, 2007

Age, mo	Subjects, No.	Seroprevalence, %, Subjects			Dose(s), No., Median
		Type 1	Type 2	Type 3	mOPV1	mOPV3	tOPVa
6	57	79	49	65	3	2	1
7	64	77	63	73	3	2	2
8	84	86	76	73	3	2	2
9	79	90	76	78	3	3	3
10	76	95	75	71	4	3	3
11	83	94	73	80	5	3	2
12	24	96b	79c	92d	5	4	4

Abbreviations: mOPV1, type 1 monovalent oral poliovirus vaccine; mOPV3, type 3 monovalent oral poliovirus vaccine; tOPV, trivalent oral poliovirus vaccine.

^aIncluded 0–5 doses received through routine immunization and 0–1 dose received through vaccination campaigns.

^bP < .0001.

^cP < .01.

^dP < .05, by the Cochran test for trend.